Advanced search
Publication Cover
Expert Review of Vaccines Volume 8, 2009 - Issue 10
Submit an article Journal homepage
289
Views
59
CrossRef citations to date
0
Altmetric
Review

Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience

Jianglong Zhu Research Fellow, Bioorganic Chemistry Laboratory, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. [email protected]
,
J David Warren Assistant Professor, Biochemistry, Director, Abby and Howard P. Milstein Chemistry Core Facility, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA. [email protected]
&
Samuel J Danishefsky Head, Bioorganic Chemistry Laboratory, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA and Professor of Chemistry, Department of Chemistry, Columbia University, Havemeyer Hall, New York, NY 10027, USA. [email protected]
Pages 1399-1413 | Published online: 09 Jan 2014

References

  • Seyrek K. The third alphabet of life: carbohydrate–protein interactions. Turk. J. Vet. Anim. Sci.28, 784–792 (2004).
  • Varki A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology3, 97–130 (1993).
  • Haltiwanger RS, Lowe JB. Role of glycosylation in development. Annu. Rev. Biochem.73, 491–537 (2004).
  • Easton RL, Patankar MS, Lattanzio FA et al. Structural analysis of murine zona pellucida glycans. J. Biol. Chem.275, 7731–7742 (2000).
  • Sutton-Smith M, Wong NK, Khoo K-H et al. Analysis of protein-linked glycosylation in a sperm-somatic cell adhesion system. Glycobiology17, 553–567 (2007).
  • Aitken RJ. The complexities of conception. Science269, 39–40 (1995).
  • Florman HM, Wassarman PM. O-linked oligosaccharides of mouse egg ZP3 account for its sperm receptor activity. Cell41, 313–324 (1985).
  • Henderson JK, Draper JS, Baillie HS et al.Preimplantation human embryos and embryonic stem cells show comparable expression of stage-specific embryonic antigens. Stem Cells20, 329–337 (2002).
  • Pennington JE, Rastan S. Roelcke D, Feizi T. Saccharide structures of the mouse embryo during the first eight days of development. J. Embryol. Exp. Morphol.87, 115–128 (1985).
  • Fenderson BA, Eddy EM, Hakomori S-I. Glycoconjugate expression during embryogenesis and its biological significance. BioEssays12, 173–179 (1990).
  • Schwarting GA, Yamamoto M. Expression of glycoconjugates during development of the vertebrate nervous system. BioEssays9, 19–23 (1988).
  • Blum AS, Barnstable CJ. O-acetylation of a cell-surface carbohydrate creates discrete molecular patterns during neural development. Proc. Natl Acad. Sci. USA84, 8716–8720 (1987).
  • Yang CR, Liour SS, Dasgupta S, Yu RK. Inhibition of neuronal migration by JONES antibody is independent of 9-O-acetyl GD3 in GD3-synthase knockout mice. J. Neurosci. Res.85, 1381–1390 (2007).
  • Miyaki M, Zenita K. Tanaka O, Okada Y, Kannagi R. Stage-specific expression of SSEA-1-related antigens in the developing lung of human embryos and its relation to the distribution of these antigens in lung cancers. Cancer Res.48, 7150–7158 (1988).
  • Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl Acad. Sci. USA99, 10231–10233 (2002).
  • Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res.56, 5309–5318 (1996).
  • Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta1473, 21–34 (1999).
  • Livingston PO, Zhang S, Lloyd KO. Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol. Immunother.45, 1–9 (1997).
  • Slovin SF, Keding SJ, Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol. Cell Biol.83, 418–428 (2005).
  • Le Poole IC, Gerberi MAT, Kast WM. Emerging strategies in tumor vaccines. Curr. Opin. Oncol.14, 641–648 (2002).
  • Dzhambazov B, Holmdahl M, Yamada H et al. The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans. Eur. J. Immunol.35, 357–366 (2005).
  • Purcell AW, van Driel, IR, Gleeson PA. Impact of glycans on T-cell tolerance to glycosylated self-antigens. Immunol. Cell Biol.86, 574–579 (2008).
  • Xu Y, Sette A, Sidney J, Gendler SJ, Franco A. Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention. Immunol. Cell Biol.83, 440–448 (2005).
  • Bettahi I, Dasgupta G, Renaudet O et al. Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B-cell, CD4+ and CD8+ T cell epitopes. Cancer Immunol. Immunother.58, 187–200 (2009).
  • Ingale S, Wolfert MA, Buskas T, Boons GJ. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. Chembiochem.10, 455–463 (2009).
  • Halcomb RL, Danishefsky SJ. On the direct epoxidation of glycals: application of a reiterative strategy for the synthesis of β-linked oligosaccharides. J. Am. Chem. Soc.111, 6661–6666 (1989).
  • Danishefsky DJ, Bilodeau MT. Glycals in organic synthesis: the evolution of comprehensive strategies for the assembly of oligosaccharides and glycoconjugates of biological consequence. Angew. Chem. Int. Ed.35, 1381–1419 (1996).
  • Ouerfelli O, Warren JD, Wilson RM, Danishefsky SJ. Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities. Expert Rev. Vaccines4(5), 677–685 (2005).
  • Kannagi R, Levery SB, Ishigami F et al. New globo series glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen. J. Biol. Chem.258, 8934–8942 (1983).
  • Bremer EG, Levery SB, Sonnino S et al. Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. J. Biol. Chem.259, 14773–14777 (1984).
  • Livingston PO. Augmenting the immunogenicity of carbohydrate tumor antigens. Semin. Cancer Biol.6, 357–366 (1995).
  • Bilodeau MT, Park TK, Danishefsky SJ et al. Total synthesis of a human breast tumor associated antigen. J. Am. Chem. Soc.117, 7840–7841 (1995).
  • Park TK, Kim IJ, Hu SH et al. Total synthesis and proof of structure of a human breast tumor (Globo-H) antigen. J. Am. Chem. Soc.118, 11488–11500 (1996).
  • Allen JR, Allen JG, Zhang XF et al. A second generation synthesis of the MBr1 (Globo-H) breast tumor antigen: new application of the n-pentenyl glycoside method for achieving complex carbohydrate protein linkages. Chem. Eur. J.6, 1366–1375 (2000).
  • Ragupathi G, Park TK, Zhang SL et al. Immunization of mice with a fully synthetic globo-H antigen results in antibodies against human cancer cells: a combined chemical–immunological approach to the fashioning of an anticancer vaccine. Angew. Chem. Int. Ed.36, 125–128 (1997).
  • Ragupathi G, Slovin SF, Adluri S et al. A fully synthetic globo-H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: a proof of principle. Angew. Chem. Int. Ed.38, 563–566 (1999).
  • Slovin SF, Ragupathi G, Adluri S et al. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo-H hexasaccharide conjugate in man. Proc. Natl Acad. Sci. USA96, 5710–5715 (1999).
  • Gilewski T, Ragupathi G, Danishefsky SJ et al. Immunization of metastatic breast cancer patients with a fully synthetic globo-H conjugate: a Phase I trial. Proc. Natl Acad. Sci. USA98, 3270–3275 (2001); erratum in: Proc. Natl Acad. Sci. USA98, 14186 (2001).
  • Dickler MN, Ragupathi G, Liu NX et al. Immunogenicity of a fucosyl–GM1–keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin. Cancer Res.5(10), 2773–2779 (1999).
  • Krug LM, Ragupathi G, Danishefsky SJ et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM1 conjugated to keyhole limpet hemocyanin. Clin. Cancer Res.10(18 Pt 1), 6094–6100 (2004).
  • Sabbatini PJ, Kudryashov V, Danishefsky SJ et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a Phase 1 trial. Int. J. Cancer87(1), 79–85 (2000).
  • Carlstedt I, Davies JR. Glycoconjugates facing the outside world. Biochem. Soc. Trans.25, 214–219 (1997).
  • Chen XT, Sames D, Danishefsky SJ. Exploration of modalities in building O-linked systems through glycal assembly: a total synthesis of the mucin-related F1 antigen. J. Am. Chem. Soc.120(31), 7760–7769 (1998).
  • Kuduk SD, Schwarz JB, Danishefsky SJ et al. Synthetic and immunological studies on clustered modes of mucin-related TN and TF O-linked antigens: the preparation of a glycopeptide-based vaccine for clinical trials against prostate cancer. J. Am. Chem. Soc.120, 12474–12485 (1998).
  • Kagan E, Ragupathi G, Danishefsky SJ et al. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol. Immunother.54, 424–430 (2005).
  • Slovin SF, Ragupathi G, Danishefsky SJ et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with -N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J. Clin. Oncol.11, 4292–4298 (2003).
  • Schwarz JB, Kuduk SD, Danishefsky SJ et al. A broadly applicable method for the efficient synthesis of O-linked glycopeptides and clustered sialic acid residues. J. Am. Chem. Soc.121, 2662–2673 (1999).
  • Sames D, Chen XT, Danishefsky SJ. Convergent total synthesis of a tumor-associated mucin motif. Nature389, 587–591 (1997).
  • Glunz PW, Hintermann, S, Williams LJ et al. Design and synthesis of Ley-bearing glycopeptides that mimic cell surface Ley mucin glycoprotein architecture. J. Am. Chem. Soc.122, 7273–7279 (2000).
  • Ragupathi G, Cappello S, Danishefsky SJ et al. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine20, 1030–1038 (2002).
  • Ragupathi G, Koide F, Sathyan N et al. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Cancer Immunol. Immunother.52, 608–616 (2003).
  • Slovin SF, Ragupathi G, Fernandez C et al. A polyvalent vaccine for high-risk prostate patients: ‘are more antigens better?’ Cancer Immunol. Immunother.56, 1921–1930 (2007).
  • Sabbatini PJ, Ragupathi G, Hood C et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS-21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin. Cancer Res.13, 4170 (2007).
  • Barington T, Gyhrs A, Kristensen K, Heilmann C. Opposite effect of actively and passively acquired immunity to the carrier on response of human infants to Haemophilus influenzae type b conjugate vaccine. Infect. Immun.62, 9–14 (1994).
  • Peters CC, Tenbergen-Meeks AM, Poolman JT et al. Effect of carrier priming on immunogenicity of saccharide–protein conjugate vaccines. Infect. Immun.59, 3504–3510 (1974).
  • Sarvas H, Makela O, Toivanen P, Toivanen A. Effect of carrier preimmunization on the anti-hapten response in chicken. Scand. J. Immunol.3, 455–460 (1974).
  • Herzenberg LA, Tokuhisa T. Carrier-priming leads to hapten-specific suppression. Nature285, 664–667 (1980).
  • Kihlberg J, Elofsson M. Solid-phase synthesis of glycopeptides: immunological studies with T cell stimulating glycopeptides. Curr. Med. Chem.4, 85–116 (1997).
  • Sears P, Wong CH. Carbohydrate mimetics: a new strategy for tackling the problem of carbohydrate-mediated biological recognition. Angew. Chem. Int. Ed. Engl.28, 2300–2324 (1999).
  • Muller B, Schaub C, Schmidt RR. Efficient sialyltransferase inhibitors based on transition-state analogs of the sialyl donor. Angew. Chem. Int. Ed.37, 2893–2897 (1998).
  • Glunz PW, Hintermann S, Williams LJ et al. Design and synthesis of ley-bearing glycopeptides that mimic cell surface ley mucin glycoprotein architecture. J. Am. Chem. Soc.122, 7273–7279 (2000).
  • Allen JR, Allen JG, Zhang XF et al. A second generation synthesis of the MBr1 (Globo-H) breast tumor antigen: new application of the N-pentenyl glycoside method for achieving complex carbohydrate protein linkages. Chem. Eur. J.6, 1366–1375 (2000).
  • Allen JR, Ragupathi G, Livingston PO, Danishefsky SJ. New applications of the N-pentenyl glycoside method in the synthesis and immunoconjugation of fucosyl GM1: a highly tumor-specific antigen associated with small cell lung carcinoma J. Am. Chem. Soc.121, 10875–10882 (1999).
  • Allen JR, Harris CR, Danishefsky SJ. Pursuit of optimal carbohydrate-based anticancer vaccines: preparation of a multiantigenic unimolecular glycopeptide containing the Tn, MBr1, and Ley antigens. J. Am. Chem. Soc.123, 1890–1897 (2001).
  • Biswas K, Coltart DM, Danishefsky SJ. Construction of carbohydrate-based antitumor vaccines: synthesis of glycosyl amino acids by olefin cross-metathesis. Tetrahedron Lett.43, 6107–6110 (2002).
  • Wan Q, Cho YS, Lambert TH, Danishefsky SJ. Olefin cross-metathesis: a powerful tool for constructing vaccines composed of multimeric antigens. J. Carbohydr. Chem.24, 425–440 (2005).
  • Zhu J, Wan Q, Ragupathi G, George CM, Livingston PO, Danishefsky SJ. Biologics through chemistry: total synthesis of a proposed dual acting vaccine targeting ovarian cancer by orchestration of oligosaccharide and polypeptide domains. J. Am. Chem. Soc.131, 4151–4158 (2009).
  • Cho YS, Wan Q, Danishefsky SJ. Organic synthesis in pursuit of immunology: large-scale synthesis of peracetylated GM2 glycosylamino acid for preparation of a multiantigenic prostate cancer vaccine. Bioorg. Med. Chem.13, 5259–5266 (2005).
  • Zhu J, Wan Q, Yang G, Ouerfelli O, Danishefsky SJ. Synthesis of human cancer associated globo-H (MBr1 antigen) glycosylamino acid: some mechanistic and conformational reinvestigations. Heterocycles79, 441–449 (2009).
  • Keding SJ, Endo A, Biswas K et al. Hydroxynorleucine as a glycosyl acceptor is an efficient means for introducing amino acid functionality into complex carbohydrates. Tetrahedron Lett.44, 3413–3416 (2003).
  • Keding SJ, Endo A, Danishefsky SJ. Synthesis of non-natural glycosylamino acids containing tumor-associated carbohydrate antigens. Tetrahedron59, 7023–7031 (2003).
  • Ragupathi G, Coltart DM, Williams LJ et al. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc. Natl Acad. Sci. USA99, 13699–13704 (2002).
  • Keding SJ, Danishefsky SJ. Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors. Proc. Natl Acad. Sci. USA101, 11937–11942 (2004).
  • Ragupathi G, Koide F, Livingston PO et al. Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates. J. Am. Chem. Soc.128, 2715–2725 (2006).
  • Livingston PO, Natoli EJ, Calves MJ et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl Acad. Sci. USA84, 2911–2915 (1987).
  • Livingston PO, Wong GY, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. Clin. Oncol.12, 1036–1044 (1994).
  • Zhu J, Danishefsky SJ. A unimolecular pentavalent carbohydrate-based antigen KLH conjugate as vaccine targeting prostate and breast cancer. Chin. Sci. Bull.53, 2126 (2008).
  • Zhu J, Wan Q, Lee D et al. From synthesis to biologics: preclinical data on the chemistry derived anticancer vaccines. J. Am. Chem. Soc.131, 9298–9303 (2009).
  • Kiguchi K, Iwamori Y, Suzuki N et al. Characteristic expression of globotriaosyl ceramide in human ovarian carcinoma-derived cells with anticancer drug resistance. Cancer Sci.97, 1321–1326 (2006).
  • Giuntoli RL, Rodriguez GC, Whitaker RS et al. Mucin gene expression in ovarian cancers. Cancer Res.58, 5546–5550 (1998).
  • Tampellini M, Berruti A, Gerbino A et al. Relationship between CA 15–3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br. J. Cancer75, 698–702 (1997).
  • Bon GG, Verheijen RHM, Zuetenhorst JM et al. Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon. Gynecol. Obstet. Inv.42, 58–62 (1996).
  • Nakamori S, Ota DM, Cleary KR, Shirotani K, Irimura T. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gasteroenterology106, 353–361 (1994).
  • Gendler SJ, Lancaster CA, Taylor-Papadimitriou T et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem.265, 15286–15293 (1990).
  • Butts C, Murray N, Maksymiuk A et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol.23, 6674–6681 (2005).
  • Lee D, Danishefsky SJ. ‘Biologic’ level structures through chemistry: a total synthesis of a unimolecular pentavalent MUCI glycopeptide construct. Tetrahedron Lett.50, 2167–2170 (2009).
  • Southwood S, Sidney J, Kondo A et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immun.160, 3363–3373 (1998).
  • Nagorny P, Kim, WH, Wan Q et al. On the emerging role of chemistry in the fashioning of biologics: synthesis of a bidomainal fucosyl GM1-based vaccine, for the treatment of small cell lung cancer. J. Org. Chem.74(15), 5157–5162 (2009).
  • Zhang S, Cordon-Cardo C, Zhang HS et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer73, 42–49 (1997).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.